Medifron DBT Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.00%

Medifron DBT Co. Ltd (065650) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 065650 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩470.00

≈ $0.32 USD Cash + Short-term Investments

Total Assets

₩113.62 Billion

≈ $77.00 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Medifron DBT Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 065650 total assets.

Liquid Assets Composition Over Time

This chart breaks down Medifron DBT Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Medifron DBT Co. Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩470.00	0.0%
Total Liquid Assets	₩470.00	0.00%

Asset Resilience Insights

Limited Liquidity: Medifron DBT Co. Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Medifron DBT Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Medifron DBT Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Medifron DBT Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Medifron DBT Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	12.61%	₩7.62 Billion ≈ $5.16 Million	₩60.40 Billion ≈ $40.94 Million	-10.69pp
2023-12-31	23.30%	₩13.00 Billion ≈ $8.81 Million	₩55.79 Billion ≈ $37.81 Million	-23.65pp
2022-12-31	46.95%	₩26.18 Billion ≈ $17.74 Million	₩55.75 Billion ≈ $37.78 Million	+27.36pp
2021-12-31	19.59%	₩9.62 Billion ≈ $6.52 Million	₩49.10 Billion ≈ $33.27 Million	-9.97pp
2020-12-31	29.57%	₩13.96 Billion ≈ $9.46 Million	₩47.22 Billion ≈ $32.00 Million	-21.61pp
2019-12-31	51.17%	₩9.96 Billion ≈ $6.75 Million	₩19.46 Billion ≈ $13.19 Million	-14.19pp
2018-12-31	65.37%	₩14.10 Billion ≈ $9.56 Million	₩21.57 Billion ≈ $14.62 Million	+8.58pp
2017-12-31	56.78%	₩14.90 Billion ≈ $10.10 Million	₩26.24 Billion ≈ $17.78 Million	+37.45pp
2016-12-31	19.33%	₩5.37 Billion ≈ $3.64 Million	₩27.75 Billion ≈ $18.81 Million	+9.60pp
2015-12-31	9.73%	₩3.00 Billion ≈ $2.03 Million	₩30.84 Billion ≈ $20.90 Million	+1.04pp
2014-12-31	8.69%	₩2.30 Billion ≈ $1.56 Million	₩26.48 Billion ≈ $17.95 Million	--

pp = percentage points

About Medifron DBT Co. Ltd

KQ:065650 Korea Biotechnology

Market Cap

$13.45 Million

₩19.84 Billion KRW

Market Cap Rank

#26398 Global

#1994 in Korea

Share Price

₩1491.00

Change (1 day)

+3.69%

52-Week Range

₩1438.00 - ₩3880.00

All Time High

₩8800.00